Orthocomp

Orthocomp

Orthopedics An injectable, nonresorbable, bone-bonding cement used in vertebroplasty for treating spinal compression fractures due to osteoporosis or carcinoma. See Vertebroplsaty.
References in periodicals archive ?
Orthovita develops, manufactures and markets the broadest platform of bone substitutes including BioGran, its first commercialized product that is a resorbable, granular biomaterial that biologically transforms to bone, OrthoComp, a composite, high strength resin cement with a biological interface that bonds to bone and is fast setting and injectable; and VitaGraft, an injectable resorbable cement that aids in fracture healing.
This press release contains forward-looking statements by the Company regarding its expectations as to CORTOSS, ORTHOCOMP and VITOSS and other aspects of its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Orthovita currently has four products under development that are derived from this technology, and branded as ORTHOCOMP Injectable, CORTOSS Injectable, CORTOSS Putty and CORTOSS Implants.
Orthovita currently has four products under development that are derived from this technology, and branded as ORTHOCOMP(TM) Injectable, CORTOSS(TM) Injectable, CORTOSS(TM) Putty and CORTOSS(TM) Implants as well as ORTHOCOMP total joint bone cement.
Orthovita has a worldwide marketing, sales and distribution agreement for joint development of ORTHOCOMP for use in joint implant procedures with Howmedica, a subsidiary of Stryker Corp.
Orthovita currently has four products under development that are derived from this technology, and branded as CORTOSS(TM) Injectable, CORTOSS(TM) Putty and CORTOSS(TM) Implants as well as ORTHOCOMP total joint bone cement.
This press release contains forward-looking statements by the Company regarding its expectations as to CORTOSS, ORTHOCOMP and VITOSS, that the spine is the fastest growing market in orthopaedics, and other aspects of its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Orthovita currently has three products under development that are derived from the Orthocomp platform, and newly branded as Cortoss Injectable, Cortoss Putty and Cortoss Implants.
Orthovita has a worldwide marketing, sales, and distribution agreement for joint development of ORTHOCOMP for use in joint implant procedures with Howmedica, a subsidiary of Stryker Corp.
Factors that may cause such a difference include, but are not limited to, problems and risks in further developing products from the Company's Orthocomp and Vitoss technology platforms for commercial sale, as well as uncertainties relating to clinical trials and in gaining regulatory approvals, uncertainties relating to market acceptance of any products commercialized and the need for additional funds to continue operations.
Currently, we have three products under development that are derived from the Orthocomp platform, and newly branded as Cortoss(TM) Injectable, Cortoss(TM) Putty and Cortoss(TM) Implants.
The clinical investigations are designed to demonstrate the safety and efficacy of Orthocomp for augmenting the screws used in plate constructs for fracture repair where the screws fail to hold due to poor bone quality.